Results 51 to 60 of about 9,921 (221)

The cell cycle‐related genes RHAMM, AURKA, TPX2, PLK1, and PLK4 are associated with the poor prognosis of breast cancer patients

open access: yesJournal of Cellular Biochemistry, 2022
Breast cancer is the third most common type of cancer diagnosed. Cell cycle is a complex but highly organized and controlled process, in which normal cells sense mitogenic growth signals that instruct them to enter and progress through their cell cycle ...
Iris Kahl   +8 more
semanticscholar   +1 more source

Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer

open access: yesTherapeutic Advances in Medical Oncology, 2019
Backgrounds: Despite the clinical success of taxanes, they still have limitations, such as chemoresistance. To overcome the limitations of paclitaxel, genetic alterations and targeting effects of altered genes were observed in paclitaxel-resistant cancer.
Sol-Bi Shin, Sang-Uk Woo, Hyungshin Yim
doaj   +1 more source

Plk1: unexpected roles in DNA replication [PDF]

open access: yesCell Research, 2013
FOR20, a conserved centrosomal protein, is essential for Plk1 to localize to the centrosome during the S phase and regulate DNA replication. The absence of either Plk1 or FOR20 can stall the cell cycle by a previously unknown intra-S phase centrosomal checkpoint.
Ranadip, Mandal, Klaus, Strebhardt
openaire   +2 more sources

PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma

open access: yesCell Death and Differentiation, 2021
The prerequisite function of vimentin for the epithelial–mesenchymal transition (EMT) is not clearly elucidated yet. Here, we show that vimentin phosphorylated by PLK1, triggers TGF-β-signaling, which consequently leads to metastasis and PD-L1 expression
Hay-Ran Jang   +6 more
semanticscholar   +1 more source

Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer

open access: yesExpert Opinion on Drug Discovery, 2022
Introduction Polo Like Kinase 1 (PLK1) is a key regulator of mitosis and its overexpression is frequently observed in a wide variety of human cancers, while often being associated with poor survival rates.
Jessy M. Stafford   +2 more
semanticscholar   +1 more source

Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer

open access: yesAdvancement of science, 2021
Dysregulation of the cell cycle machinery leads to genomic instability and is a hallmark of cancer associated with chemoresistance and poor prognosis in colorectal cancer (CRC).
Zhao-liang Yu   +19 more
semanticscholar   +1 more source

Targeting PLK1-CBX8-GPX4 axis overcomes BRAF/EGFR inhibitor resistance in BRAFV600E colorectal cancer via ferroptosis

open access: yesNature Communications
Metastatic BRAFV600E colorectal cancer (CRC) confers poor prognosis and represents a therapeutic bottleneck. To identify resistance mechanisms of the mitogen-activated protein kinase (MAPK) pathway in BRAFV600E CRC, we perform genome-wide CRISPR-Cas9 ...
Zhan Zhao   +21 more
semanticscholar   +1 more source

Interaction of Chromatin-associated Plk1 and Mcm7 [PDF]

open access: yesJournal of Biological Chemistry, 2005
Plk1 is a multifunctional protein kinase involved in regulation of mitotic entry, chromosome segregation, centrosome maturation, and mitotic exit. Plk1 is a target of DNA damage checkpoints and aids resumption of the cell cycle during recovery from G2 arrest.
Lyuben, Tsvetkov, David F, Stern
openaire   +2 more sources

Polo-like kinase 1 promotes Cdc42-induced actin polymerization for asymmetric division in oocytes

open access: yesOpen Biology, 2023
Polo-like kinase I (Plk1) is a highly conserved seronine/threonine kinase essential in meiosis and mitosis for spindle formation and cytokinesis. Here, through temporal application of Plk1 inhibitors, we identify a new role for Plk1 in the establishment ...
Wai Shan Yuen   +5 more
doaj   +1 more source

PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities

open access: yesFrontiers in Immunology
PLK1 plays a crucial role in cell cycle regulation and cancer development, and its dysregulation has been implicated in the prognosis of a variety of malignancies. The potential of PLK1 inhibitors as cancer therapeutics has been extensively investigated.
Weihao Wang   +5 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy